ATE230263T1 - At1 rezeptor antagonist zur anregung von apoptosis - Google Patents
At1 rezeptor antagonist zur anregung von apoptosisInfo
- Publication number
- ATE230263T1 ATE230263T1 AT97903313T AT97903313T ATE230263T1 AT E230263 T1 ATE230263 T1 AT E230263T1 AT 97903313 T AT97903313 T AT 97903313T AT 97903313 T AT97903313 T AT 97903313T AT E230263 T1 ATE230263 T1 AT E230263T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonist
- apoptosis
- stimulating apoptosis
- pharmaceutical
- stimulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH52296 | 1996-02-29 | ||
PCT/EP1997/000757 WO1997031634A1 (en) | 1996-02-29 | 1997-02-18 | At1 receptor antagonist for the stimulation of apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE230263T1 true ATE230263T1 (de) | 2003-01-15 |
Family
ID=4188936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97903313T ATE230263T1 (de) | 1996-02-29 | 1997-02-18 | At1 rezeptor antagonist zur anregung von apoptosis |
Country Status (11)
Country | Link |
---|---|
US (1) | US6174910B1 (de) |
EP (1) | EP0883401B1 (de) |
JP (1) | JP4369994B2 (de) |
AT (1) | ATE230263T1 (de) |
AU (1) | AU1791497A (de) |
CY (1) | CY2456B1 (de) |
DE (1) | DE69718146T2 (de) |
DK (1) | DK0883401T3 (de) |
ES (1) | ES2189940T3 (de) |
PT (1) | PT883401E (de) |
WO (1) | WO1997031634A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1588706E (pt) * | 1998-12-23 | 2011-12-21 | Novartis Ag | Comprimido de valsartan |
US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
EP1013273A1 (de) * | 1998-12-23 | 2000-06-28 | Novartis AG | Verwendung von AT-1 Rezeptorantagonisten oder AT-2 Rezeptormodulatoren zur Behandlung von Erkrankungen, die mit einer Erhöhung an AT-1 oder AT-2 Rezeptoren verbunden sind |
PL358290A1 (en) * | 2000-06-22 | 2004-08-09 | Novartis Ag | Pharmaceutical compositions |
DE10153737A1 (de) * | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
WO2005087267A1 (ja) * | 2004-03-12 | 2005-09-22 | Yokohama Tlo Company, Ltd. | 前立腺肥大症治療剤 |
PL1750862T3 (pl) | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
CA2874595A1 (en) * | 2007-04-13 | 2009-02-19 | Southern Research Institute | Use of terfenadine for treating breast and ovarian tumors |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
ES2142789T3 (es) | 1989-06-14 | 2000-05-01 | Smithkline Beecham Corp | Acidos imidazolil-alquenoicos. |
US5298518A (en) | 1989-09-29 | 1994-03-29 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
ES2084801T3 (es) | 1990-02-19 | 1996-05-16 | Ciba Geigy Ag | Acil compuestos. |
NZ237476A (en) | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IE912956A1 (en) | 1990-09-10 | 1992-03-11 | Abbott Lab | Angiotensin ii receptor antagonists |
US5250548A (en) * | 1990-09-10 | 1993-10-05 | Abbott Laboratories | Angiotensin II receptor antagonists |
US5614519A (en) | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
HUT71331A (en) | 1992-04-13 | 1995-11-28 | Zeneca Ltd | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
EP0635263A3 (de) * | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin (AII)-antagonisten als Inhibitoren des Wachstums von Fettgewebe. |
AU1850695A (en) * | 1994-03-17 | 1995-10-03 | Novartis Ag | Treatment of diabetic nephropathy with valsartan |
US5981470A (en) * | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
-
1997
- 1997-02-18 WO PCT/EP1997/000757 patent/WO1997031634A1/en active IP Right Grant
- 1997-02-18 AU AU17914/97A patent/AU1791497A/en not_active Abandoned
- 1997-02-18 PT PT97903313T patent/PT883401E/pt unknown
- 1997-02-18 US US09/142,003 patent/US6174910B1/en not_active Expired - Lifetime
- 1997-02-18 JP JP53055497A patent/JP4369994B2/ja not_active Expired - Fee Related
- 1997-02-18 EP EP97903313A patent/EP0883401B1/de not_active Expired - Lifetime
- 1997-02-18 DK DK97903313T patent/DK0883401T3/da active
- 1997-02-18 ES ES97903313T patent/ES2189940T3/es not_active Expired - Lifetime
- 1997-02-18 DE DE69718146T patent/DE69718146T2/de not_active Expired - Lifetime
- 1997-02-18 AT AT97903313T patent/ATE230263T1/de active
-
2004
- 2004-06-04 CY CY0400043A patent/CY2456B1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE69718146D1 (de) | 2003-02-06 |
JP4369994B2 (ja) | 2009-11-25 |
DE69718146T2 (de) | 2003-10-02 |
EP0883401B1 (de) | 2003-01-02 |
JP2000505465A (ja) | 2000-05-09 |
CY2456B1 (en) | 2005-06-03 |
DK0883401T3 (da) | 2003-05-05 |
US6174910B1 (en) | 2001-01-16 |
ES2189940T3 (es) | 2003-07-16 |
AU1791497A (en) | 1997-09-16 |
WO1997031634A1 (en) | 1997-09-04 |
PT883401E (pt) | 2003-03-31 |
EP0883401A1 (de) | 1998-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU20600A (sh) | Nova upotreba antagonista 5-ht3 receptora | |
DE69738754D1 (de) | Hemmer der interaktion zwischen p53 und mdm2 | |
GEP20094798B (en) | (s,s)-reboxetine for treating chronic pain | |
EP1463827A4 (de) | LIMKs ALS MODIFIKATOREN DES P53-WEGS SOWIE VERWENDUNGSVERFAHREN | |
ATE299710T1 (de) | Methoden zur behandlung von muskelerkrankungen und muskelstörungen | |
AU2002327378A1 (en) | Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation | |
YU38801A (sh) | Azabicikloalkani kao modulatori ccr5 | |
HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
TR200001795T2 (tr) | 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı. | |
WO2002097395A3 (en) | P-cadherin as a target for anti-cancer therapy | |
WO2003087831A3 (en) | Proteins involved in breast cancer | |
ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
FR2760369B1 (fr) | Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation | |
UA66865C2 (uk) | Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти) | |
MY124786A (en) | Bis-arylsulfones | |
EA199900912A1 (ru) | Фармацевтические средства | |
ATE230263T1 (de) | At1 rezeptor antagonist zur anregung von apoptosis | |
ATE357917T1 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
DE59608150D1 (de) | Transdermales therapeutisches system (tts) zur verabreichung von testosteron | |
TR200103638T2 (tr) | IL-8 Reseptör antagonistleri | |
MXPA02001204A (es) | Compuestos calciliticos. | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
PL336897A1 (en) | Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts | |
GB9924941D0 (en) | Treatment of dyskinesia | |
WO1999050671A3 (en) | Toso as a target for drug screening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEIH | Change in the person of patent owner | ||
UEP | Publication of translation of european patent specification |
Ref document number: 0883401 Country of ref document: EP |